CO-005, a humanized anti-CD47 fusion protein from Caedo Oncology, showed potent antitumor activity in preclinical models of B-cell lymphoma, including rituximab-resistant tumors. The therapy induces programmed cancer cell death while disrupting immune checkpoints, offering a potential solution to CD20 resistance.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
Next-generation in vivo CAR-T therapy enables cancer treatment with a single injection, while new Texas legislation and community-based delivery models expand patient access to this advanced cellular therapy.
The CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. The Cell & Gene Therapy Drug Delivery Devices Market is forecast to climb to USD 26.79 billion by 2032 from USD 3.39 billion in 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775508 |
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma |
RECRUITING | PHASE1 |
| NCT07652580 |
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma |
RECRUITING | |
| NCT07616089 |
Phase I Study of FXS0683 in the Treatment of Blood Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07593482 |
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07520006 |
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07516093 |
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL |
NOT_YET_RECRUITING | PHASE3 |
| NCT07474051 |
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials |
ENROLLING_BY_INVITATION | |
| NCT07369492 |
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma |
RECRUITING | PHASE1 |
| NCT07211048 |
Anti CD19 Gene Therapy for B-cell Lymphoma |
RECRUITING | NA |
| NCT07168486 |
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas |
ENROLLING_BY_INVITATION | PHASE1 |
